Dong Kim - Jan 31, 2024 Form 4/A Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jan 31, 2024
Transactions value $
$0
Form type
4/A
Date filed
2/12/2024, 05:47 PM
Date Of Original Report
Feb 2, 2024
Previous filing
Sep 8, 2023
Next filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +3.33K +10.44% 35.3K Jan 31, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 This amendment corrects and restates the Amount of Securities Beneficially Owned Following Reported Transaction reported in the original Form 4 filed on February 2, 2024.